FDA Updates Guidance On Lab Data For New Drugs
In its draft guidance, the FDA focused on so-called analytical procedures — essentially, lab tests that evaluate a drug’s attributes. The document applies to most forms of approval applications, including those for new brand-name drugs, generics and biologics.
The guidance is expected to supersede policies previously outlined in 2000, and...
To view the full article, register now.